Menu
Not yet recruiting NCT07242391

Menopausal Hormone Therapy And Left Ventricular Function

— Observational Menopause Left Ventricular Dysfunction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Menopausal Hormone Therapy.
Who it may be relevant to
Registry conditions: Menopause, Left Ventricular Dysfunction. Basic parameters: 45 years — 60 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Menopausal Hormone Therapy And Neural Control Of Left Ventricular Function

Overview

The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.

Interventions

  • Drug Menopausal Hormone Therapy
    Taken in accordance with standard clinical practice, administered for a minimum duration of eight weeks.

Primary outcome measures

  • Left ventricular stroke volume [Time frame: Baseline]
Secondary outcome measures (1)
  • Ventriculo-Arterial (VA) coupling [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • >45-60< years of age

Exclusion criteria

  • Male sex
  • Females between STRAW+10 stages -5 and 0
  • PMF in STRAW+10 stage +2
  • PMF using oral hormone therapy
  • Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)
  • Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction
  • Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI.
  • Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI.
  • Pregnancy
  • COPD
  • Diabetes
  • CKD
  • Raynaud's phenomenon
  • Sleep disorders
  • Shift workers
  • BMI ≥40.0kg/m2
  • Use of nicotine-containing products within the two years preceding study visits
  • Active cancer treatment

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Other

Study locations

United States · 1 center
  • Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT07242391 · 25-006388

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗